Ulster University Logo

Ulster Institutional Repository

The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse

Biomedical Sciences Research Institute Computer Science Research Institute Environmental Sciences Research Institute Nanotechnology & Advanced Materials Research Institute

JOINER, B, HIRST, VK, McKeown, SR, MCALEER, JJA and HIRST, DG (1993) The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse. British Journal of Cancer, 68 (4). pp. 720-726. [Journal article]

Full text not available from this repository.

Abstract

Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Faculty of Life and Health Sciences > School of Health Sciences
Research Institutes and Groups:Institute of Nursing and Health Research > Centre for Health and Rehabilitation Technologies
ID Code:15095
Deposited By:Miss Anna Mooney
Deposited On:31 Aug 2010 13:01
Last Modified:01 Mar 2012 09:50

Repository Staff Only: item control page